Senetek has struck a deal to acquire RNAi technology for brain tumors from the Institute of Bioorganic Chemistry of the Polish Academy of Sciences. The deal includes the rights to three anti-aging compounds for skin. The brain tumor technology is designed to inhibit the production of tenascin-C, which is linked to malignancy. "This new technology works not only to prolong the survival of patients suffering from brain tumors, but possibly to cure them as well," said CEO Frank Massino. RNAi technology has turned red-hot in the wake of this year's Nobel Prize for the field's pioneers.
- check out the UPI report on Senetek
ALSO: Nastech struck a licensing deal with City of Hope for RNAi technology. Release